Glucosamine and Chondroitin Effects (GLANCE)

Fred Hutchinson Cancer Center (FHCC)

Status

Completed

Conditions

Inflammation

Treatments

Dietary Supplement: placebo

Dietary Supplement: Glucosamine and Chondroitin

Study type

Interventional

Funder types

Other

Identifiers

NCT01682694

7798 (Other Identifier)

Details and patient eligibility

About

A common starting dose of glucosamine and chondroitin will reduce inflammation as reflected by a reduction in serum C-reactive protein.

Full description

Use of glucosamine and chondroitin have been associated with reduced cancer and overall mortality. The aim of this study is to determine whether a common starting dose of glucosamine and chondroitin (1500 mg/d + 1200 mg/d, respectively) reduces systemic inflammation as reflected by a reduction in high sensitivity C-reactive protein.

Enrollment

20 patients

Sex

All

Ages

20 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy
Overweight (body mass index kg/m2 (BMI) between 25 and 32.5)
Non-smoking men and women
Aged 20-55y

Exclusion criteria

Chronic medical illness, history of gastrointestinal, hepatic, or renal disorders, or inflammatory conditions (including autoimmune and inflammatory diseases)
Pregnancy or lactation
Currently on a weight-loss diet
BMI (body mass index) < 25 or > 30
Alcohol intake of greater than 2 drinks/day
Current use of prescription or over-the-counter medications, (Excluding oral contraceptives and hormone-secreting IUDs), including use of aspirin or NSAIDs more than 2 days per week
Abnormal renal, liver or metabolic test
Inability to swallow pills
Known allergy to shellfish
Not willing to take pills made from shellfish or animal sources
Intention to relocate out of study area within next 4 months